Treatment rates and healthcare costs of patients with fragility fracture by site of care: a real-world data analysis

Andrea Singer, Michael R. McClung, Oth Tran, +5

Archives of Osteoporosis

Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on <i>nab</i>-paclitaxel plus gemcitabine versus FOLFIRINOX

Ali McBride, Machaon Bonafede, Qian Cai, +5

Expert Review of Clinical Pharmacology

Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a USA-Based Electronic Health Records Database

Jennie H. Best, Amanda M. Kong, Sebastian Unizony, +2

Rheumatology and Therapy

Long-term direct and indirect economic burden associated with osteoporotic fracture in US postmenopausal women

Oth Tran, Stuart L. Silverman, Xiaoqing Xu, +4

Osteoporosis International

Commercial claims costs related to health care resource use associated with a diagnosis of peanut allergy

Marcus Shaker, J. Chalil, Oth Tran, +5

Annals of Allergy Asthma & Immunology

Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions

Jay Margolis, Steven Deitelzweig, Jeffrey A. Kline, +5

Journal of the American Heart Association

The Impact of Allergy Specialty Care on Health Care Utilization Among Peanut Allergy Children in the United States

Matthew Greenhawt, Elissa M. Abrams, J. Chalil, +3

The Journal of Allergy and Clinical Immunology In Practice

Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US

Jeffrey D. Miller, Xin Ye, Gregory Lenhart, +5

ClinicoEconomics and Outcomes Research

Productivity Loss and Indirect Costs for Patients Newly Diagnosed with Early- versus Late-Stage Cancer in the USA: A Large-Scale Observational Research Study

Ze Cong, Oth Tran, J.H. Nelson, +2

Applied Health Economics and Health Policy

Pulmonary Embolism Inpatients Treated With Rivaroxaban Had Shorter Hospital Stays and Lower Costs Compared With Warfarin

Jay Margolis, Steven Deitelzweig, Jeffrey A. Kline, +5

Clinical Therapeutics